

Johanne I Weberpals

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2564799/publications.pdf>

Version: 2024-02-01

31
papers

2,086
citations

566801

15
h-index

525886

27
g-index

31
all docs

31
docs citations

31
times ranked

3366
citing authors

#	ARTICLE	IF	CITATIONS
1	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1949-1961.	6.3	1,261
2	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e173776.	3.4	116
3	The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. <i>International Journal of Cancer</i> , 2009, 124, 806-815.	2.3	88
4	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 710-722.	5.1	70
5	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4767-4776.	3.2	68
6	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. <i>Gynecologic Oncology</i> , 2015, 137, 216-222.	0.6	65
7	Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway. <i>Journal of Clinical Oncology</i> , 2008, 26, 3259-3267.	0.8	61
8	Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. <i>Cancer Genetics</i> , 2011, 204, 525-535.	0.2	49
9	Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3. <i>Clinical Cancer Research</i> , 2017, 23, 4501-4510.	3.2	45
10	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. <i>Clinical Cancer Research</i> , 2018, 24, 6168-6174.	3.2	44
11	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021, 7, 1772.	3.4	44
12	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3494-3505.	0.8	28
13	Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2559-2571.	1.9	22
14	The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells. <i>Cancer Cell International</i> , 2011, 11, 29.	1.8	20
15	A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. <i>Journal of Translational Medicine</i> , 2016, 14, 83.	1.8	18
16	Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. <i>British Journal of Cancer</i> , 2021, 125, 1666-1676.	2.9	18
17	A Rare Case of Ectopic Adrenocorticotrophic Hormone Syndrome in Small Cell Carcinoma of the Vagina. <i>Journal of Lower Genital Tract Disease</i> , 2008, 12, 140-145.	0.9	14
18	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 159, 101-111.	0.6	14

#	ARTICLE	IF	CITATIONS
19	Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 3045-3058.	1.3	11
20	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 949-958.	1.2	7
21	Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6057-6057.	0.8	7
22	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. <i>Cancer Medicine</i> , 2021, 10, 7162-7173.	1.3	4
23	Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5522-5522.	0.8	3
24	Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5608-TPS5608.	0.8	2
25	Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5537-5537.	0.8	2
26	Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5545-5545.	0.8	2
27	Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5561-5561.	0.8	2
28	Outcomes of recurrent and metastatic endometrial cancer (RMEC) treated with systemic progestins.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5585-5585.	0.8	1
29	Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5537-5537.	0.8	0
30	Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5579-5579.	0.8	0
31	Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5544-5544.	0.8	0